FDA approves new COVID-19 vaccine

The U.S. Food and Drug Administration has approved a novel COVID-19 vaccine to treat high-risk patients.

The approval comes after the vaccine, known as mRNA-1283, demonstrated higher relative efficacy and a similar safety profile compared to a previous vaccine in a phase III trial involving more than 11,000 patients, according to a news report from PharmExec. The novel vaccine is recommended for use in patients aged 65 years and older and those aged 12 to 64 years with underlying risk factors for severe disease, as defined by the Centers for Disease Control and Prevention.

The vaccine is expected to become available in the 2025 to 2026 respiratory virus season.

Read more: PharmExec

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.